Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Nutrients ; 15(12)2023 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-37375619

RESUMEN

Nutritional and pharmacological therapies represent the basis for non-dialysis management of CKD patients. Both kinds of treatments have specific and unchangeable features and, in certain cases, they also have a synergic action. For instance, dietary sodium restriction enhances the anti-proteinuric and anti-hypertensive effects of RAAS inhibitors, low protein intake reduces insulin resistance and enhances responsiveness to epoetin therapy, and phosphate restriction cooperates with phosphate binders to reduce the net phosphate intake and its consequences on mineral metabolism. It can also be speculated that a reduction in either protein or salt intake can potentially amplify the anti-proteinuric and reno-protective effects of SGLT2 inhibitors. Therefore, the synergic use of nutritional therapy and medications optimizes CKD treatment. Quality of care management is improved and becomes more effective when compared to either treatment alone, with lower costs and fewer risks of unwanted side effects. This narrative review summarizes the established evidence of the synergistic action carried out by the combination of nutritional and pharmacological treatments, underlying how they are not alternative but complementary in CKD patient care.


Asunto(s)
Fallo Renal Crónico , Insuficiencia Renal Crónica , Sodio en la Dieta , Humanos , Fallo Renal Crónico/metabolismo , Riñón/metabolismo , Antihipertensivos/uso terapéutico , Sodio en la Dieta/uso terapéutico , Fosfatos
2.
Front Endocrinol (Lausanne) ; 14: 1124479, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37152926

RESUMEN

Background: Idiopathic hyperaldosteronism (IHA) is one of the most common types of primary aldosteronism (PA), an important cause of hypertension. Although high dietary sodium is a major risk factor for hypertension, there is no consensus on the recommended dietary sodium intake for IHA. Objective: This study investigated the effect of a low-sodium diet on hemodynamic variables and relevant disease biomarkers in IHA patients, with the aim of providing a useful reference for clinical treatment. Methods: Fifty IHA patients were evenly randomized into two groups and provided, after a 7-day run-in period (100 mmol/d sodium), either a low-sodium diet (50 mmol/d sodium) or a normal sodium diet (100 mmol/d sodium) for an additional 7 days. After the 14-day intervention (conducted without potassium supplementation), changes in blood pressure (BP) and serum potassium were evaluated in both groups. Results: After the dietary intervention, the low sodium group exhibited, compared to the normal sodium group, decreased BP (SBP: 121.8 ± 12.8 vs. 129.9 ± 12.1 mmHg, p < 0.05; DBP: 82.6 ± 7.6 vs. 86.4 ± 8.2 mmHg, p < 0.05; MAP: 95.7 ± 8.8 vs. 100.9 ± 8.4 mmHg, p < 0.05) and increased serum potassium levels (3.38 ± 0.33 vs. 3.07 ± 0.27 mmol/L, p < 0.001). The low sodium group showed also better control of both BP and serum potassium: BP <140/90 mmHg in 70.0% of total patients (76.0% vs. 64.0%, in the low and normal sodium groups, respectively; p > 0.05), BP <130/85 mmHg in 38.0% of total patients (56.0% vs. 20.0%, p < 0.05), BP <120/80 mmHg in 28.0% of total patients (44.0% vs. 12.0%, p < 0.05); serum potassium ≥3.5 mmol/L in 22.0% of total patients (32.0% vs. 12.0% in the low and normal sodium groups, respectively; p = 0.088). There were differences between the controlled BP group (<120/80 mmHg) and the non-controlled BP group (≥120/80 mmHg) in gender, BP at baseline, and type of diet (low vs. normal sodium). Female gender and low-sodium diet were protective factors for BP control. Conclusions: A low-sodium diet is effective in lowering BP and elevating serum potassium in IHA patients. Female patients on a low-sodium diet are more likely to achieve BP control (<120/80 mmHg). We advocate a dietary sodium intake of 50 mmol/d for IHA patients. Clinical trial registration: https://clinicaltrials.gov, Identifier NCT05649631.


Asunto(s)
Hiperaldosteronismo , Hipertensión , Sodio en la Dieta , Humanos , Femenino , Dieta Hiposódica , Hipertensión/etiología , Hipertensión/tratamiento farmacológico , Sodio , Sodio en la Dieta/uso terapéutico , Potasio , Hiperaldosteronismo/complicaciones , Hiperaldosteronismo/tratamiento farmacológico
3.
Inn Med (Heidelb) ; 63(10): 1097-1104, 2022 Oct.
Artículo en Alemán | MEDLINE | ID: mdl-35925119

RESUMEN

Nonpharmacological treatment is still an important supplement to the pharmacological treatment of hypertension. Thereby, either an elevated blood pressure can be lowered further or, alternatively, the use of antihypertensive drugs can be reduced. In the context of nonpharmacological treatment of hypertension, sodium restriction plays an important role. Sodium intake can either be reduced by lowering excessive dietary salt consumption or by the use of table salts with reduced sodium content. Lower dietary sodium consumption lowers blood pressure. This was controversial for a long time; however, now more and more observational and interventional studies have confirmed this fact. Nevertheless, some studies have shown an association of low salt consumption with increased mortality. This observation is explained by the so-called reverse epidemiology. This means that diseases with increased mortality, such as consuming diseases or severe heart diseases are associated with lowered food intake and as a consequence, with lower sodium intake. In addition to sodium restriction, the use of so-called salt substitutes with lower sodium content is also effective in lowering blood pressure. In most of the salt substitutes examined so far sodium chloride is partly replaced by potassium chloride. Numerous investigations show that these salt substitutes lower blood pressure. From a statistical point of view side effects such as hyperkalemia are very rare; however, hyperkalemia is potentially life-threatening. Therefore, the broader use of these salt substitutes is principally helpful but these salts should only be used after medical consultation. Especially renal insufficiency and the use of certain drugs, such as potassium-sparing diuretics and blockers of the renin-angiotensin system increase the risk of hyperkalemia.


Asunto(s)
Hiperpotasemia , Hipertensión , Sodio en la Dieta , Antihipertensivos/efectos adversos , Diuréticos/efectos adversos , Humanos , Hiperpotasemia/inducido químicamente , Hipertensión/tratamiento farmacológico , Preparaciones Farmacéuticas , Potasio/uso terapéutico , Cloruro de Potasio/farmacología , Sales (Química)/uso terapéutico , Sodio/uso terapéutico , Cloruro de Sodio/uso terapéutico , Cloruro de Sodio Dietético/efectos adversos , Sodio en la Dieta/uso terapéutico
4.
Nutrients ; 13(9)2021 Aug 26.
Artículo en Inglés | MEDLINE | ID: mdl-34578838

RESUMEN

Gitelman's (GS) and Bartter's (BS) syndromes are rare, inherited autosomal recessive tubulopathies characterized by hypokalemia, metabolic alkalosis, renal sodium, chloride, and potassium and magnesium-wasting. While the treatment based on potassium, sodium, chloride, and magnesium supplementation in addition to other pharmacologic options are widely established, recommendations about the dietary approach to GS and BS still remain generic. In this review we focus on the dietary strategies to increase sodium, potassium, and magnesium intake in GS and BS patients. Potassium and magnesium-rich foods and supplements are considered together with those that may reduce through different mechanisms the potassium and magnesium plasma level. Magnesium supplementation is often poorly tolerated, causing abdominal pain and diarrhea in most patients. New formulations using liposome and, in particular, sucrosomial technology have been recently proposed for magnesium supplementation in order to increase magnesium supplement tolerability and intestinal absorption. The dietary approach to GS and BS may be very important in the therapeutic approach to these syndromes. Due to the relevance of the dietary approach to these syndromes, a nutritional counseling should always be recommended and the nutritionist should join nephrologists in the follow-up of GS and BS patient care.


Asunto(s)
Síndrome de Bartter/dietoterapia , Dieta/métodos , Síndrome de Gitelman/dietoterapia , Magnesio/uso terapéutico , Potasio en la Dieta/uso terapéutico , Sodio en la Dieta/uso terapéutico , Humanos
5.
Proc Nutr Soc ; 78(4): 540-546, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-30853033

RESUMEN

Micronutrient deficiencies are widespread and disproportionately affect women and children in low- and middle-income countries (LMIC). Among various interventions, food fortification and supplementation with micronutrients have been proven to be cost-effective. The aim of the present paper is to review existing literature to assess risks of excessive intake in LMIC to then highlight programmatic changes required to maximise benefits of micronutrient interventions while minimising risks of adverse effects. While very few LMIC have national food consumption surveys that can inform fortification programmes, many more are implementing mandatory fortification programmes. The risks of inadequate micronutrient intakes were common, but risks of excessive intakes were also present for iodine, vitamin A, folic acid and iron. Excessive salt consumption, high concentrations of iodine in ground-water and excessive levels of iodisation were linked with excessive iodine intake. For vitamin A, overlapping interventions were the main risk for excessive intake; whereas for iron, contamination with iron from soil and screw-wares of millers and high iron concentration in drinking-water increased the risk of excessive intake, which could be further exacerbated with fortification. Before implementing micronutrient interventions, adherence to the basic principles of documenting evidence confirming that the deficiency in question exists and that fortification will correct this deficiency is needed. This can be supported with dietary intake assessments and biochemical screening that help diagnose nutrient deficiencies. Targeting micronutrient interventions, although programmatically challenging, should be considered whenever possible. Moreover, closer monitoring of appropriate fortification of foods and overlapping interventions is needed.


Asunto(s)
Enfermedades Carenciales , Suplementos Dietéticos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Alimentos Fortificados , Micronutrientes , Enfermedades Carenciales/tratamiento farmacológico , Enfermedades Carenciales/prevención & control , Países en Desarrollo , Ácido Fólico/administración & dosificación , Ácido Fólico/efectos adversos , Ácido Fólico/uso terapéutico , Humanos , Yodo/efectos adversos , Yodo/uso terapéutico , Hierro/administración & dosificación , Hierro/efectos adversos , Hierro/uso terapéutico , Micronutrientes/administración & dosificación , Micronutrientes/efectos adversos , Micronutrientes/uso terapéutico , Pobreza , Sodio en la Dieta/efectos adversos , Sodio en la Dieta/uso terapéutico
6.
Acta Paediatr ; 104(7): e294-9, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25703573

RESUMEN

AIM: Managing neonatal Bartter syndrome by achieving adequate weight gain is challenging. We assessed the correlation between weight gain in neonatal Bartter syndrome and the introduction of fluid and sodium supplementations and indomethacin during the first 4 weeks of life. METHODS: Daily fluid and electrolytes requirements were analysed using linear regression and Spearman correlation coefficients. The weight gain coefficient was calculated as daily weight gain after physiological neonatal weight loss. RESULTS: We studied seven infants. The highest weight gain coefficients occurred between weeks two and four in the five neonates who either received prompt amounts of fluid (maximum 810 mL/kg/day) and sodium (maximum 70 mmol/kg/day) or were treated with indomethacin. For the two patients with the highest weight gain coefficient, water and sodium supplementations were decreased in weeks two to four leading to a significant negative Spearman correlation between weight gain and fluid supplements (r = -0.55 and -0.68) and weight gain and sodium supplementations (r = -0.96 and -0.72). The two patients with the lowest weight gain coefficient had positive Spearman correlation coefficients between weight gain and fluid and sodium supplementations. CONCLUSION: Infants with neonatal Bartter syndrome required rapid and enormous fluid and sodium supplementations or the early introduction of indomethacin treatment to achieve adequate weight gain during the early postnatal period.


Asunto(s)
Síndrome de Bartter/terapia , Suplementos Dietéticos , Fluidoterapia , Sodio en la Dieta/uso terapéutico , Aumento de Peso , Factores de Edad , Estudios de Cohortes , Inhibidores de la Ciclooxigenasa/uso terapéutico , Femenino , Humanos , Indometacina/uso terapéutico , Recién Nacido , Masculino
7.
Acta Astronaut ; 50(12): 765-74, 2002 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-12053941

RESUMEN

Bed rest (BR) induces significant urinary and blood electrolyte changes, but little is known about the effect of fluid and salt supplements (FSS) on catabolism, hydration and electrolytes. The aim was to measure the effect of FSS on catabolism, body hydration and electrolytes during BR. Studies were done during 7 days of a pre-bed rest period and during 30 days of a rigorous bed rest period. Thirty male athletes aged, 24.6 +/- 7.6 years were chosen as subjects. They were divided into three groups: unsupplemented ambulatory control subjects (UACS), unsupplemented bed rested subjects (UBRS) and supplemented bed rested subjects (SBRS). The UBRS and SBRS groups were kept under a rigorous bed rest regime for 30 days. The SBRS daily took 30 ml water per kg body weight and 0.1 sodium chloride per kg bodyweight. Plasma sodium (Na), potassium (K), calcium (Ca) and magnesium (Mg) levels, urinary Na, K, Ca and Mg excretion, plasma osmolality, plasma protein level, whole blood hemoglobin (Hb) and hematocrit (Hct) level increased significantly (p < or = 0.05), while plasma volume (PV), body weight, body fat, peak oxygen uptake, food and fluid intake decreased significantly (p < or = 0.05) in the UBRS group when compared with the SBRS and UACS groups. In contrast, plasma and urinary electrolytes, osmolality, protein level, whole blood Hct and Hb level decreased significantly (p < or = 0.05), while PV, fluid intake, body weight and peak oxygen uptake increased significantly (p < or = 0.05) in the SBRS group when compared with the UBRS group. The measured parameters did not change significantly in the UACS group when compared with their baseline control values. The data indicate that FSS stabilizes electrolytes and body hydration during BR, while BR alone induces significant changes in electrolytes and body hydration. We conclude that FSS may be used to prevent catabolism and normalize body hydration status and electrolyte values during BR.


Asunto(s)
Adaptación Fisiológica/fisiología , Reposo en Cama , Fluidoterapia , Aptitud Física/fisiología , Sodio en la Dieta/uso terapéutico , Equilibrio Hidroelectrolítico/efectos de los fármacos , Adolescente , Adulto , Proteínas Sanguíneas/metabolismo , Calcio/sangre , Calcio/orina , Humanos , Magnesio/sangre , Magnesio/orina , Masculino , Concentración Osmolar , Consumo de Oxígeno , Volumen Plasmático/efectos de los fármacos , Volumen Plasmático/fisiología , Potasio/sangre , Potasio/orina , Carrera , Sodio/sangre , Sodio/orina , Equilibrio Hidroelectrolítico/fisiología
8.
Nutr Metab Cardiovasc Dis ; 11(3): 158-67, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11590991

RESUMEN

BACKGROUND AND AIM: Recent clinical studies have demonstrated that plant sterols moderately lower serum cholesterol levels in patients with mild hypercholesterolemia. Furthermore, there is evidence suggesting that mineral nutrients, such as calcium and magnesium, may also decrease serum cholesterol concentrations. In this study, we tested the hypothesis that supplementation with mineral nutrients may enhance the cholesterol-lowering effect of plant sterols in obese Zucker rats. Furthermore, we compared the lipid-lowering effects of monovalent sodium and potassium cations with those of divalent calcium and magnesium cations. METHODS AND RESULTS: A Western-type high-fat/high-cholesterol diet increased serum cholesterol by 175% and liver cholesterol by 65% in comparison with a low-fat/low-cholesterol control diet. On the contrary, the high-fat/high-cholesterol diet decreased intestinal cholesterol absorption, as assessed by means of serum campesterol-, sitosterol-, and sitostanol-to-cholesterol ratios, thus indicating that it was under negative feedback regulation. Supplementation of the high-fat/high-cholesterol diet with plant sterols or mineral nutrients partially prevented the diet-induced increased in serum cholesterol and, when given concurrently, their cholesterol-lowering effect was enhanced. Their combination also effectively prevented the diet-induced increase in liver cholesterol concentration, and had beneficial effects on liver and myocardial hypertrophy, and the development of obesity. These beneficial effects were at least partially mediated by an enhanced blockade of intestinal cholesterol absorption. Interestingly, only divalent cations enhanced the cholesterol-lowering effect of plant sterols, thus supporting the idea that the lipid-lowering effect of divalent cations is related to the formation of insoluble and inabsorbable calcium and magnesium chelates with fatty acids. CONCLUSIONS: Our findings indicate that the cholesterol-lowering effect of plant sterols is enhanced by the co-administration of divalent calcium and magnesium cations but not by monovalent sodium and potassium cations.


Asunto(s)
Calcio de la Dieta/uso terapéutico , Colesterol/sangre , Magnesio/uso terapéutico , Obesidad/dietoterapia , Fitosteroles/uso terapéutico , Análisis de Varianza , Animales , Calcio de la Dieta/sangre , Calcio de la Dieta/orina , Electrólitos/orina , Femenino , Metabolismo de los Lípidos , Magnesio/sangre , Obesidad/sangre , Potasio en la Dieta/uso terapéutico , Potasio en la Dieta/orina , Ratas , Ratas Zucker , Sodio en la Dieta/uso terapéutico , Sodio en la Dieta/orina
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA